Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study

• Published in: Transplantation and cellular therapy 2024-02, Vol.30 (2), p.S82-S83
• Main Authors: Hill, Joshua A., Martens, Michael J., Young, Jo-Anne H., Bhavsar, Kavita, Kou, Jianqun, Chen, Min, Lee, Lik Wee, Baluch, Aliyah, Dhodapkar, Madhav Vishnu, Nakamura, Ryotaro, Peyton, Kristin, Shahid, Zainab, Armistead, Paul M., Westervelt, Peter, McCarty, John M., McGuirk, Joseph P, Hamadani, Mehdi, DeWolf, Susan, Hosszu, Kinga, Sharon, Elad, Spahn, Ashley, Toor, Dr. Amir A., Waldvogel, Stephanie, Greenberger, Lee M., Auletta, Dr. Jeffery J., Horowitz, Mary M., Riches, Marcie L., Perales, Miguel-Angel
• Format: Article
• Language: English
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2023.12.134

We previously reported the immunogenicity of SARS-CoV-2 vaccination within the first year after allogeneic hematopoietic cell transplant (HCT) from CIBMTR SC21-07/BMT CTN 2101. We herein report updated results from the full allogeneic HCT cohort in addition to the autologous HCT and CAR-T cell therapy cohorts. We conducted a prospective multicenter study of individuals who initiated SARS-CoV-2 vaccinations within 12 months of allogenic HCT, autologous HCT, or CAR-T cell therapy. We obtained blood prior to and after each vaccine dose for up to 4 vaccine doses, with an end-of-study sample 7 to 9 months after enrollment. We tested for SARS-CoV-2 spike protein (anti-S) IgG; nucleocapsid protein (anti-N) IgG; and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains in all participants (LabCorp), in addition to SARS-CoV-2-specific T-cell receptors (TCRs) in a subgroup (n=151; Adaptive Biotech). We established a relevant threshold for immunogenicity assessment using receiver operating characteristic curves to determine the anti-S IgG threshold predictive of median neutralizing antibody levels (≥5274 ID50) achieved in a non-immunocompromised cohort vaccinated with two doses of mRNA-1273. We compared the proportion of participants with anti-S IgG titers above this threshold among those initiating vaccination